PRTA - Novo Nordisk boosts Prothena on plans for amyloidosis therapy
2025-08-06 10:03:06 ET
More on Novo Nordisk, Prothena
- GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
- Novo Nordisk Is Now A Better Value Play Than Eli Lilly With Solid Upside
- Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
- Novo Nordisk plans cost cuts amid slower Wegovy growth outlook
- Novo Nordisk GAAP EPADR of DKK 12.49, revenue of DKK 154.94B; updates FY outlook